MedTrace Logo

Aflibercept in Patients With Pigment Epithelial Detachments (PED)

NCT03370380 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2018-08-06

No results posted yet for this study

Summary

Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to AMD

Conditions

  • Pigment Epithelial Detachment

Interventions

DRUG

Aflibercept

Patients are treated according to authorization of Aflibercept

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Christoph Clemens, Dr. med. · University Hospital Muenster

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-17
Primary Completion
2018-04-23
Completion
2018-04-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03370380 on ClinicalTrials.gov